New Three-Drug cocktail targets Hard-to-Treat lymphoma
NCT ID NCT04447716
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing the safety and best dose of a three-drug combination (venetoclax, lenalidomide, and rituximab) in patients with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. The study enrolled only 4 participants to see how well the drugs work together and what side effects occur. If successful, this approach might provide a new treatment option for these slow-growing but difficult-to-treat lymphomas.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax, lenalidomide, and rituximab
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for patients with relapsed or refractory indolent non-Hodgkin lymphoma.
- What could go wrong
- This is a very early phase 1 trial with only 4 participants, so results may not apply broadly. The drug combination may cause significant side effects or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted drug combo aims to tackle Hard-to-Treat lymphoma
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug combo shows early promise for recurrent lymphoma
- Engineered immune cells take on tough blood cancers in early trial
- Gene therapy takes on HIV and cancer in one shot
- New combo shows promise for rare blood cancer